ALX Oncology’s (ALXO) Overweight Rating Reaffirmed at Cantor Fitzgerald

ALX Oncology (NASDAQ:ALXO)‘s stock had its “overweight” rating restated by analysts at Cantor Fitzgerald in a report released on Friday,Benzinga reports. Cantor Fitzgerald also issued estimates for ALX Oncology’s FY2025 earnings at ($2.21) EPS.

Several other brokerages have also recently weighed in on ALXO. HC Wainwright decreased their price objective on shares of ALX Oncology from $25.00 to $5.00 and set a “buy” rating on the stock in a research note on Friday. Jefferies Financial Group cut shares of ALX Oncology from a “buy” rating to a “hold” rating and decreased their price objective for the stock from $12.00 to $2.00 in a research note on Thursday, December 19th. Three research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat.com, ALX Oncology presently has a consensus rating of “Moderate Buy” and an average price target of $3.50.

ALX Oncology Price Performance

NASDAQ ALXO traded down $0.15 on Friday, reaching $1.49. The company’s stock had a trading volume of 511,327 shares, compared to its average volume of 1,200,371. The company has a current ratio of 4.82, a quick ratio of 4.82 and a debt-to-equity ratio of 0.07. The firm has a market cap of $78.32 million, a PE ratio of -0.50 and a beta of 0.98. ALX Oncology has a 52 week low of $1.19 and a 52 week high of $17.83. The business has a 50-day moving average price of $1.61 and a 200 day moving average price of $2.42.

Insider Activity at ALX Oncology

In other news, Director Rekha Hemrajani bought 30,000 shares of the business’s stock in a transaction on Monday, December 2nd. The shares were bought at an average cost of $1.55 per share, for a total transaction of $46,500.00. Following the completion of the acquisition, the director now owns 33,000 shares in the company, valued at approximately $51,150. This trade represents a 1,000.00 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have sold 14,443 shares of company stock worth $23,309 over the last ninety days. Company insiders own 33.40% of the company’s stock.

Institutional Investors Weigh In On ALX Oncology

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Hsbc Holdings PLC acquired a new stake in shares of ALX Oncology during the second quarter worth $63,000. AQR Capital Management LLC grew its position in ALX Oncology by 50.7% in the second quarter. AQR Capital Management LLC now owns 18,079 shares of the company’s stock valued at $109,000 after purchasing an additional 6,080 shares in the last quarter. SG Americas Securities LLC grew its position in ALX Oncology by 33.6% in the third quarter. SG Americas Securities LLC now owns 27,394 shares of the company’s stock valued at $50,000 after purchasing an additional 6,888 shares in the last quarter. Algert Global LLC bought a new position in ALX Oncology in the second quarter valued at $249,000. Finally, GSA Capital Partners LLP bought a new position in ALX Oncology in the third quarter valued at $88,000. 97.97% of the stock is currently owned by institutional investors and hedge funds.

ALX Oncology Company Profile

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.